Craig Dorrell

Oregon Health & Science University — United States

Medicine · Health Sciences

30h-index8.1kcitations103works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(37), Neuroendocrine Tumor Research Advances(30), Pancreatitis Pathology and Treatment(30), Pancreatic function and diabetes(30), Liver physiology and pathology(14)

Publications103 total

In vivo assessment of differential toxicity of cancer treatment drugs in Fanconi’s Anemia
2025Open Access
Glucagon and GLP-1 Accelerate Pseudo-Islet Assembly and Unmask Sex-Specific Islet Fragmentation Dynamics
2025Open Access
Long‐term combination therapy with metformin and oxymetholone in a Fanconi anemia mouse model
Pediatric Blood & Cancer·2024· 2 cited
In vivo tracing of the Cytokeratin 14 lineages using self-cleaving guide RNAs and CRISPR/Cas9
Developmental Biology·2023Open Access
Long-term combination therapy with Metformin and Oxymetholone in a Fanconi Anemia mouse model
2023Open Access
Supplementary Figures from A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression
2023Open Access
Data from A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression
2023Open Access
Supplementary Table 2 from A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression
2023Open Access
Supplementary Table 2 from A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression
2023Open Access
Supplementary Methods from A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression
2023Open Access
Supplementary Table 1 from A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression
2023Open Access
Supplementary Methods from A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression
2023Open Access
Supplementary Table 1 from A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression
2023Open Access
Data from A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression
2023Open Access
Supplementary Figures from A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression
2023Open Access
Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
2023Open Access
Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
2023Open Access
Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
2023Open Access
Supplementary Figure from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
2023Open Access
Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Markus Grompe(30), Philip R. Streeter(10), Klaus H. Kaestner(9), Pamela Canaday(9), John E. Dick(9), Jonathan Schug(8), Olga I. Gan(8), Milton J. Finegold(7), Rosalie C. Sears(5), Daniel S. Pereira(5), Annelise Haft(4), Guillermo Güenechea(4), Olga Smirnova(4), Feorillo Galivo(4), Maria T. Grompe(3), Robert G. Hawley(3), Laura Erker(3), Alan J. Fox(3), Caryn Y. Ito(3), Leslie Wakefield(3)